Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial

This article was originally published here

Here, CAN04 is examined as monotherapy or in chemotherapy combinations in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC). All 20 patients planned for one

The post Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply